Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640315 | 0.89 | MEN1 (0.48) | SMN1; SMN2ALDH1A1GLAPKMHPGD | |
| SCHEMBL1642355 | 0.84 | EGLN3 (0.40) | EGLN1SMN1; SMN2ALDH1A1POLBGLA | |
| SCHEMBL1640531 | 0.83 | EGLN3 (0.46) | EGLN1SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL1642134 | 0.83 | ALDH1A1 (0.41) | EGLN1SMN1; SMN2ALDH1A1POLBGLA | |
| SCHEMBL1641816 | 0.83 | LMNA (0.44) | EGLN1SMN1; SMN2ALDH1A1HPGDTDP1 | |
| SCHEMBL1641443 | 0.83 | KDM4E (0.41) | SMN1; SMN2ALDH1A1POLBGLAPKM | |
| SCHEMBL1640777 | 0.81 | EGLN3 (0.45) | EGLN1SMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL1640523 | 0.81 | EGLN3 (0.47) | SMN1; SMN2ALDH1A1PKMHPGDTDP1 | |
| SCHEMBL1642157 | 0.81 | ALDH1A1 (0.41) | EGLN1SMN1; SMN2ALDH1A1GLAPKM | |
| SCHEMBL1641724 | 0.81 | EGLN1 (0.41) | EGLN1SMN1; SMN2ALDH1A1GLAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2306828-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxosmithkline LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885SMN1; SMN2 3631/4885ALDH1A1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.